Intismeran autogene Clinical Trials (2026): 12 Studies for Non-small Cell Lung Cancer & Melanoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
12 Intismeran autogene clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 10 indications (including Non-small Cell Lung Cancer & Melanoma) and 5,137 total planned enrollment. 4 Phase 3 Intismeran autogene trials and 5 Phase 2 are listed. 5 Intismeran autogene clinical trials are actively recruiting at 105 U.S. sites across 30 states. Most recent activity: NCT07513376 (May 2038).
Where to Participate: All Intismeran autogene Trial Sites in the U.S. (105 sites across 30 states)
Every actively recruiting Intismeran autogenetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Banner MD Anderson Cancer Center ( Site 0181) | Gilbert85234 | NCT06623422 | Map |
| AZ | The University of Arizona Cancer Center - North Campus ( Site 0163) | Tucson85719 | NCT06623422 | Map |
| AR | Highlands Oncology Group ( Site 4042) | Springdale72762 | NCT06961006 | Map |
| CA | Michael G Oefelein Clinical Trials ( Site 0138) | Bakersfield93301 | NCT06833073 | Map |
| CA | Providence St. Jude Medical Center ( Site 0106) | Fullerton92835 | NCT06623422 | Map |
| CA | VA Long Beach Healthcare System ( Site 0199) | Long Beach90822 | NCT06623422 | Map |
| CA | UCLA Jonsson Comprehensive Cancer Center ( Site 0135) | Los Angeles90404 | NCT06623422 | Map |
| CA | USC Norris Comprehensive Cancer Center ( Site 0123) | Los Angeles90033 | NCT06833073 | Map |
| CA | USC Norris Comprehensive Cancer Center ( Site 0205) | Los Angeles90033 | NCT06623422 | Map |
| CA | UC Davis Comprehensive Cancer Center ( Site 3204) | Sacramento95817 | NCT07513376 | Map |
| CA | UCSF Medical Center at Mission Bay ( Site 0178) | San Francisco94158 | NCT06623422 | Map |
| CA | UCSF Medical Center at Mission Bay ( Site 4044) | San Francisco94158 | NCT06961006 | Map |
| CA | Genesis Healthcare-Torrance ( Site 0140) | Torrance90503 | NCT06833073 | Map |
| CA | Genesis Research LLC ( Site 0118) | Torrance90505 | NCT06833073 | Map |
| CO | University of Colorado Anschutz Medical Campus ( Site 0151) | Aurora80045 | NCT06623422 | Map |
| CO | University of Colorado Cancer Center ( Site 3268) | Aurora80045 | NCT07513376 | Map |
| CO | UCHealth Memorial Hospital Central ( Site 0125) | Colorado Springs80909 | NCT06623422 | Map |
| CO | Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207) | Greeley80631 | NCT06623422 | Map |
| CO | Urology Associates ( Site 0144) | Littleton80122 | NCT06833073 | Map |
| CO | Centura Health - St. Anthony North Health Campus ( Site 0189) | Westminster80023 | NCT06623422 | Map |
| CT | Smilow Cancer Center at Yale-New Haven ( Site 3253) | New Haven06511 | NCT07513376 | Map |
| CT | Yale University School of Medicine ( Site 0201) | New Haven06510 | NCT06623422 | Map |
| CT | Eastern CT Hematology & Oncology Associates ( Site 0202) | Norwich06360 | NCT06623422 | Map |
| FL | The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156) | Fort Lauderdale33316 | NCT06623422 | Map |
| FL | Urological Research Network ( Site 0133) | Hialeah33016 | NCT06833073 | Map |
| FL | Miami Cancer Institute at Baptist Health, Inc. ( Site 0214) | Miami33176 | NCT06623422 | Map |
| FL | Moffitt Cancer Center ( Site 0021) | Tampa33612 | NCT07221474 | Map |
| ID | Beacon Cancer Care ( Site 0127) | Post Falls83854 | NCT06623422 | Map |
| IL | The University of Chicago Medical Center ( Site 0118) | Chicago60637 | NCT06623422 | Map |
| IL | Associated Urological Specialists - Chicago Ridge ( Site 0139) | Chicago Ridge60415 | NCT06833073 | Map |
| IL | Illinois Cancer Care ( Site 7000) | Peoria61615 | NCT07513376 | Map |
| IN | Franciscan Health ( Site 0219) | Indianapolis46237 | NCT06623422 | Map |
| LA | Southern Urology, LLC ( Site 0145) | Lafayette70508 | NCT06833073 | Map |
| MD | Maryland Oncology Hematology (MOH) ( Site 8102) | Rockville20850 | NCT06623422 | Map |
| MA | Dana Farber Cancer Hospital ( Site 0155) | Boston02215 | NCT06623422 | Map |
| MA | Massachusetts General Hospital ( Site 0136) | Boston02114 | NCT06623422 | Map |
| MI | VA Ann Arbor Healthcare System ( Site 0019) | Ann Arbor48105 | NCT07221474 | Map |
| MO | University of Missouri Health Care ( Site 0126) | Columbia65212 | NCT06833073 | Map |
| MO | Washington University School of Medicine ( Site 0024) | St Louis63110 | NCT07221474 | Map |
| MT | Billings Clinic ( Site 3255) | Billings59101 | NCT07513376 | Map |
| NE | NHO Revive Research Institute, LLC ( Site 0137) | Lincoln68506 | NCT06833073 | Map |
| NE | NHO Revive Research Institute, LLC ( Site 3218) | Lincoln68506 | NCT07513376 | Map |
| NV | Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207) | Reno89502 | NCT07513376 | Map |
| NJ | John Theurer Cancer Center at Hackensack University Medical Center ( Site 4047) | Hackensack07601 | NCT06961006 | Map |
| NJ | Valley Health Systems - Ridgewood Campus ( Site 0010) | Paramus07652 | NCT07221474 | Map |
| NY | New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001) | Albany12206 | NCT07221474 | Map |
| NY | New York Oncology Hematology, P.C. ( Site 9000) | Albany12206 | NCT07513376 | Map |
| NY | Roswell Park Cancer Institute ( Site 0184) | Buffalo14263 | NCT06623422 | Map |
| NY | Hematology-Oncology Associates of CNY ( Site 0164) | East Syracuse13057 | NCT06623422 | Map |
| NY | Icahn School of Medicine at Mount Sinai ( Site 0116) | New York10029 | NCT06623422 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111) | New York10016 | NCT06833073 | Map |
| NY | Memorial Sloan Kettering Cancer Center ( Site 0137) | New York10065 | NCT06623422 | Map |
| NY | The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216) | New York10011 | NCT06623422 | Map |
| NY | SUNY Upstate Cancer Center ( Site 0140) | Syracuse13210 | NCT06623422 | Map |
| NY | Montefiore Medical Center ( Site 0160) | The Bronx10461 | NCT06623422 | Map |
| NY | Westchester Medical Center ( Site 0196) | Valhalla10595 | NCT06623422 | Map |
| NY | White Plains Hospital ( Site 3213) | White Plains10601 | NCT07513376 | Map |
| NC | Charles George VA Medical Center ( Site 3233) | Asheville28805 | NCT07513376 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center ( Site 3250) | Chapel Hill27514 | NCT07513376 | Map |
| NC | Novant Health Weisiger Cancer Insititute ( Site 0266) | Charlotte28204 | NCT06623422 | Map |
| NC | WakeMed Raleigh Campus ( Site 3214) | Raleigh27610 | NCT07513376 | Map |
| NC | Novant Health Forsyth Medical Center ( Site 0166) | Winston-Salem27103 | NCT06623422 | Map |
| ND | Sanford Fargo Medical Center ( Site 3236) | Fargo58102 | NCT07513376 | Map |
| ND | Altru Health System ( Site 3254) | Grand Forks58201 | NCT07513376 | Map |
| OH | TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122) | Cincinnati45212 | NCT06833073 | Map |
| OH | University of Cincinnati Medical Center ( Site 0119) | Cincinnati45219 | NCT06623422 | Map |
| OH | Cleveland Clinic - Ohio ( Site 0016) | Cleveland44195 | NCT07221474 | Map |
| OR | Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025) | Corvallis97330 | NCT07221474 | Map |
| OR | Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0217) | Corvallis97330 | NCT06623422 | Map |
| OR | OHSU Knight Cancer Institute - South Waterfront ( Site 0110) | Portland97239 | NCT06833073 | Map |
| PA | MidLantic Urology ( Site 0102) | Bala-Cynwyd19004 | NCT06833073 | Map |
| PA | St. Lukes Hospital and Health Network ( Site 0186) | Bethlehem18015 | NCT06623422 | Map |
| PA | Perelman Center for Advanced Medicine ( Site 3205) | Philadelphia19104 | NCT07513376 | Map |
| SD | Avera Cancer Institute ( Site 3209) | Sioux Falls57105 | NCT07513376 | Map |
| SD | Sanford Cancer Center ( Site 3266) | Sioux Falls57104 | NCT07513376 | Map |
| TN | Tennessee Oncology, PLLC - Chattanooga Downtown ( Site 0315) | Chattanooga37403 | NCT06623422 | Map |
| TN | The Conrad Pearson Clinic ( Site 0143) | Germantown38138 | NCT06833073 | Map |
| TN | The University of Tennessee Medical Center ( Site 3223) | Knoxville37920 | NCT07513376 | Map |
| TN | Thompson Cancer Survival Center ( Site 0168) | Knoxville37916 | NCT06623422 | Map |
| TN | Elliston Place Medical Oncology & Hematology ( Site 0215) | Nashville37203 | NCT06623422 | Map |
| TN | Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000) | Nashville37203 | NCT07221474 | Map |
| TX | Texas Oncology - Central/South Texas ( Site 8002) | Austin78745 | NCT07221474 | Map |
| TX | Texas Oncology-Austin Central ( Site 0107) | Austin78705 | NCT06833073 | Map |
| TX | Urology Austin, PLLC ( Site 0109) | Austin78759 | NCT06833073 | Map |
| TX | Texas Oncology - DFW ( Site 8103) | Dallas75246 | NCT06623422 | Map |
| TX | UT Southwestern Medical Center ( Site 0190) | Dallas75390 | NCT06623422 | Map |
| TX | Houston Methodist Cancer Center ( Site 0191) | Houston77030 | NCT06623422 | Map |
| TX | MD Anderson Cancer Center ( Site 0150) | Houston77030 | NCT06623422 | Map |
| TX | Memorial Hermann Cancer Center ( Site 0172) | Houston77030 | NCT06623422 | Map |
| TX | Michael E. DeBakey VA Medical Center ( Site 0197) | Houston77030 | NCT06623422 | Map |
| TX | O'Quinn Medical Tower at McNair Campus ( Site 0131) | Houston77030 | NCT06623422 | Map |
| TX | The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148) | Tyler75701 | NCT06623422 | Map |
| VA | Inova Schar Cancer Institute ( Site 4046) | Fairfax22031 | NCT06961006 | Map |
| VA | Virginia Cancer Specialists ( Site 0003) | Fairfax22031 | NCT07221474 | Map |
| VA | Virginia Cancer Specialists ( Site 0167) | Fairfax22031 | NCT06623422 | Map |
| VA | Hematology Oncology Associates of Fredericksburg ( Site 3275) | Fredericksburg22408 | NCT07513376 | Map |
| VA | Virginia Oncology Associates (VOA) ( Site 8101) | Norfolk23502 | NCT06623422 | Map |
| VA | VCU Health Adult Outpatient Pavillion ( Site 0193) | Richmond23219 | NCT06623422 | Map |
| VA | Urology of Virginia ( Site 0125) | Virginia Beach23462 | NCT06833073 | Map |
| WA | Fred Hutchinson Cancer Center ( Site 4041) | Seattle98109 | NCT06961006 | Map |
| WA | Swedish Cancer Institute ( Site 0143) | Seattle98104 | NCT06623422 | Map |
| WA | Swedish Medical Center-Swedish Cancer Institute ( Site 0023) | Seattle98104 | NCT07221474 | Map |
| WA | University of Washington - Fred Hutchinson Cancer Center ( Site 0100) | Seattle98195 | NCT06833073 | Map |
| WA | St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192) | Silverdale98383 | NCT06623422 | Map |
| WV | West Virginia University ( Site 3237) | Morgantown26506 | NCT07513376 | Map |
Intismeran autogene clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | terminated | Total |
|---|---|---|---|---|
| P1 | 1 | 1 | ||
| P1/P2 | 1 | 1 | ||
| P2 | 3 | 2 | 5 | |
| P2/P3 | 1 | 1 | ||
| P3 | 2 | 2 | 4 |
Recruiting Intismeran autogene clinical trials (5)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07513376 | INTerpath-014A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) | P3 | Non-small Cell Lung Cancer | 876 | May 2026 |
| NCT06623422 | MK-3475A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | P3 | Carcinoma, Non-Small-Cell Lung | 680 | Oct 2024 |
| NCT06961006 | V940A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | P2 | Malignant Melanoma | 160 | May 2025 |
| NCT06833073 | V940A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | P2 | Urinary Bladder Neoplasms | 308 | Mar 2025 |
| NCT07221474 | INTerpath-13A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | P2 | Squamous Non-small Cell Lung Cancer | 180 | Dec 2025 |
Intismeran autogene clinical trials by indication
Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03897881 | KEYNOTE-942 | P2 | active not recruiting | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) |
| NCT05933577 | V940 | P3 | active not recruiting | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) |
Non-small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07513376 | INTerpath-014 | P3 | recruiting | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) |
| NCT06077760 | INTerpath-002 | P3 | active not recruiting | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03313778 | KEYNOTE-603 | P1 | active not recruiting | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors |
Carcinoma, Squamous Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06295809 | INTerpath-007 | P2/P3 | terminated | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) |
Bladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06305767 | V940 | P1/P2 | active not recruiting | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) |
Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06307431 | INTerpath-004 | P2 | active not recruiting | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). |
Carcinoma, Non-Small-Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06623422 | MK-3475 | P3 | recruiting | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) |
Urinary Bladder Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06833073 | V940 | P2 | recruiting | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) |
Malignant Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06961006 | V940 | P2 | recruiting | A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) |
Squamous Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07221474 | INTerpath-13 | P2 | recruiting | A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) |
Intismeran autogene pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| INTerpath-014 | NCT07513376 | P3 | recruiting | Non-small Cell Lung Cancer | 876 | — |
| MK-3475 | NCT06623422 | P3 | recruiting | Carcinoma, Non-Small-Cell Lung | 680 | — |
| INTerpath-002 | NCT06077760 | P3 | active not recruiting | Non-small Cell Lung Cancer | 868 | — |
| V940 | NCT05933577 | P3 | active not recruiting | Melanoma | 1,089 | — |
| KEYNOTE-942 | NCT03897881 | P2 | active not recruiting | Melanoma | 267 | — |
| INTerpath-004 | NCT06307431 | P2 | active not recruiting | Renal Cell Carcinoma | 272 | — |
| V940 | NCT06961006 | P2 | recruiting | Malignant Melanoma | 160 | — |
| V940 | NCT06833073 | P2 | recruiting | Urinary Bladder Neoplasms | 308 | — |
| INTerpath-13 | NCT07221474 | P2 | recruiting | Squamous Non-small Cell Lung Cancer | 180 | — |
Terminated and withdrawn Intismeran autogene trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06295809terminatedA Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
All Intismeran autogene trials (12)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07513376 | INTerpath-014 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) | P3 | recruiting | 876 | Merck Sharp & Dohme LLC | May 2026 |
| NCT06623422 | MK-3475 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | P3 | recruiting | 680 | Merck Sharp & Dohme LLC | Oct 2024 |
| NCT06077760 | INTerpath-002 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | P3 | active not recruiting | 868 | Merck Sharp & Dohme LLC | Dec 2023 |
| NCT03897881 | KEYNOTE-942 | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | P2 | active not recruiting | 267 | ModernaTX, Inc. | Jul 2019 |
| NCT06307431 | INTerpath-004 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | P2 | active not recruiting | 272 | Merck Sharp & Dohme LLC | Apr 2024 |
| NCT06305767 | V940 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | P1/P2 | active not recruiting | 230 | Merck Sharp & Dohme LLC | Mar 2024 |
| NCT06961006 | V940 | A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | P2 | recruiting | 160 | Merck Sharp & Dohme LLC | May 2025 |
| NCT06833073 | V940 | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | P2 | recruiting | 308 | Merck Sharp & Dohme LLC | Mar 2025 |
| NCT07221474 | INTerpath-13 | A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | P2 | recruiting | 180 | Merck Sharp & Dohme LLC | Dec 2025 |
| NCT05933577 | V940 | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | P3 | active not recruiting | 1,089 | Merck Sharp & Dohme LLC | Jul 2023 |
| NCT03313778 | KEYNOTE-603 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors | P1 | active not recruiting | 161 | ModernaTX, Inc. | Aug 2017 |
| NCT06295809 | INTerpath-007 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) | P2/P3 | terminated | 46 | Merck Sharp & Dohme LLC | Apr 2024 |
Intismeran autogene clinical trials: frequently asked questions
- How many Intismeran autogene clinical trials are there?
- 12 Intismeran autogene clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants.
- Are Intismeran autogene clinical trials recruiting in 2026?
- Yes — 5 Intismeran autogene trials are actively recruiting in 2026, with 105 U.S. sites across 30 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Intismeran autogene being studied for?
- Intismeran autogene is being studied for Non-small Cell Lung Cancer, Melanoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Malignant Melanoma and 8 more. The trials are grouped by indication on this page.
- What phase is Intismeran autogene in?
- Intismeran autogene clinical trials span 4 Phase 3, 5 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Intismeran autogene clinical trials?
- The lead sponsor across the most Intismeran autogene trials is Merck Sharp & Dohme LLC, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Intismeran autogeneas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: